SIGNORIA.NS,0P0001SJZL,4000
SIGNORIA · General/Diversified · NSE
₹142
Current Market Price
Fair Value (DCF)
₹83
Margin of Safety
-41.6%
Updated just now
YieldIQ Score
52/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
12%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹67 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
—
EBIT covers interest
Current Ratio
—
Short-term liquidity
Asset Turnover
0.63×
Revenue per ₹ of assets
Revenue CAGR (3Y)
32.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹141.7
Bear case
₹44.8
MoS -216.3%
Base case
₹82.77
MoS -71.2%
Bull case
₹110.99
MoS -27.7%
Ratio Trends
Historical ratio trends for SIGNORIA are being prepared. Once ready, this section will show multi-year trajectories of ROE, ROCE, margins, leverage, and valuation multiples.
Historical Financials
Historical financials for SIGNORIA are being prepared. Check back shortly for a 5-year view of revenue, earnings, cash flow, and balance-sheet trends.
Peer Comparison
Peers not yet ranked for SIGNORIA. Comparable companies and side-by-side valuation will appear here once the peer set is established.
Dividend History
No dividend events recorded for SIGNORIA in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SIGNORIA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SIGNORIA →
Compare
Head-to-head with peers
Compare SIGNORIA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SIGNORIANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.